# **COVID-19** severity prediction based on patient risk factors

# and number of vaccines received

Ariel Israel, M.D., Ph.D.<sup>1</sup> *ORCID 0000-0003-4389-8896* Alejandro A. Schäffer, Ph.D.<sup>2</sup> *ORCID 0000-0002-2147-8033* Eugene Merzon, M.D.<sup>13</sup> *ORCID 0000-0001-5469-0236* Ilan Green, M.D.<sup>14</sup> *ORCID 0000-0002-9435-7152* Eli Magen, M.D., Ph.D.<sup>15</sup> *ORCID 0000-0002-7713-423X* Avivit Golan-Cohen, M.D.<sup>14</sup> *ORCID 0000-0003-2406-6402* Shlomo Vinker, M.D., M.H.A.<sup>14</sup> *ORCID 0000-0001-9804-7103* Eytan Ruppin, M.D., Ph.D <sup>2</sup> *ORCID 0000-0002-7862-3940* 

#### **Authors Affiliations:**

<sup>1</sup> Leumit Health Services, Israel

<sup>2</sup> Cancer Data Science Laboratory, Center for Cancer Research, National Cancer Institute, Bethesda, MD USA

<sup>3</sup> Adelson School of Medicine, Ariel University, Ariel, Israel.

<sup>4</sup> Department of Family Medicine, Sackler Faculty of Medicine, Tel-Aviv University, Israel.

<sup>5</sup> Medicine C Department, Clinical Immunology and Allergy Division, Barzilai University Medical Center, Ben-Gurion University of the Negev, Ashkelon, Israel.

# **Corresponding Author:**

Ariel Israel, MD, PhD

Head of Leumit Research Institute

Leumit Health Services

Telephone: +972-58-5333212

Email: dr.ariel.israel@gmail.com

# COVID-19 severity prediction based on patient risk factors and number of vaccines received

# Abstract

## Background

Vaccines are highly effective in preventing severe disease and death from COVID-19, and new medications that can reduce severity of disease have been approved. However, many countries are facing limited supply of vaccine doses and medications. A model estimating the probabilities for hospitalization and mortality according to individual risk factors and vaccine doses received could help prioritize vaccination and yet scarce medications to maximize lives saved and reduce the burden on hospitalization facilities.

# Methods

Electronic health records from 101,034 individuals infected with SARS-CoV-2, since the beginning of the pandemic and until November 30, 2021 were extracted from a national healthcare organization in Israel. Logistic regression models were built to estimate the risk for subsequent hospitalization and death based on the number of BNT162b2 mRNA vaccine doses received and few major risk factors (age, sex, body mass index, hemoglobin A1C, kidney function, and presence of hypertension, pulmonary disease or malignancy).

#### Results

The models built predict the outcome of newly infected individuals with remarkable accuracy: area under the curve was 0.889 for predicting hospitalization, and 0.967 for predicting mortality. Even when a breakthrough infection occurs, having received three vaccination doses significantly reduces the risk of hospitalization by 66% (OR=0.336) and of death by 78% (OR=0.220).

# Conclusions

The models enable rapid identification of individuals at high risk for hospitalization and death when infected. These patients can be prioritized to receive booster vaccination and the yet scarce medications. A calculator based on these models is made publicly available on <a href="http://covidest.web.app">http://covidest.web.app</a>

Keywords: COVID-19, disease severity, calculator, diabetes, obesity, kidney disease

#### **Abbreviations:**

- AUC Area Under the Curve
- BMI Body mass Index
- COPD chronic obstructive pulmonary disease
- COVID-19 Coronavirus disease of 2019
- EHR Electronic Health Records
- GFR glomerular filtration rate
- LHS Leumit Health Services
- OR odds ratio
- ROC Receiver Operating Characteristic
- SARS-CoV-2 Severe acute respiratory syndrome coronavirus 2

# Introduction

Since the start of the COVID-19 pandemic, over 250 million individuals have been infected and over 5 million individuals have died (https://coronavirus.jhu.edu/map.html). Since late 2020, multiple vaccines have been developed<sup>1,2</sup>, and more recently, various treatments including monoclonal antibodies, and anti-viral molecules have been FDA approved<sup>3</sup>. Unfortunately, there are still not enough vaccine doses and medications available worldwide. Thus, it is an urgent unmet need to identify objectively which patients would most benefit from booster vaccination doses or early access to the yet scarce medicines<sup>4–6</sup>.

To address these questions, we conducted a retrospective study among members of Leumit Health Services (LHS), one of the four main health maintenance organizations (HMOs) in Israel, which has over 700,000 members. Our study starts at the beginning of the pandemic and hence covers periods before any vaccines were available and after. Israel was one of the first countries to implement a large-scale vaccination plan (using Pfizer/BioNTech BNT162b2 vaccine)<sup>7</sup> and to deploy a third vaccine booster dose. Nevertheless, there exists a large variation in vaccination uptake<sup>8</sup>, which provides an opportunity to assess the beneficial effects of vaccination in conjunction with other patient risk factors. In addition to vaccinations, we considered other traits associated with COVID-19 severity, including type II diabetes <sup>9–14</sup>, kidney disease <sup>11,14–16</sup>, chronic obstructive pulmonary disease (COPD) <sup>16–20</sup>, obesity<sup>10–12,21–23</sup>, hypertension <sup>24–26</sup>, malignancy<sup>27</sup> and advanced age <sup>11,28–30</sup>.

We constructed predictive models that estimate the risks that patients newly infected with SARS-CoV-2 (as reflected by positive PCR tests) would require hospitalization during the disease course and would die from COVID-19. Predictions are based on patient's age, sex, the clinical factors mentioned above and vaccination status at the time of infection (0,1,2, or 3 doses). Importantly, all these factors are typically part of a patient's medical records and measured in routine laboratory testing.

Models were built based on the outcomes of LHS patients during the study period. To keep the models simple and interpretable, and to allow deployment of the models in any health provider information system, we used multivariable logistic regression models based on the most essential risk factors. Regression coefficients and odds ratio (OR) for each factor are provided, and these can be calculated using a simple formula to obtain risk estimates for any individual. The resulting models additionally allow to estimate the decrease in hospitalization and mortality risk that can be achieved for any individual by providing additional vaccine doses. These estimates can help identify individuals and segments of population for which additional vaccination could help most. Notably, most treatments available should be given early in the course of the disease to those at high risk, to be most effective. A web-based calculator is provided, and the approach to run or adapt the models is fully described.

# Methods

#### Study subjects and study design

This is a population study performed in Leumit Health Services (LHS), a large nation-wide healthcare provider in Israel, which provides services to around 700,000 members throughout the country. LHS uses centrally managed electronic health records (EHRs), continuously updated regarding subjects' demographics, medical diagnoses, medical encounters, hospitalizations and laboratory tests. All LHS members have similar health insurance and similar access to healthcare services.

The study is based on members of LHS, of age  $\geq 5$  (eligible for vaccination), who had at least one positive PCR test for SARS-CoV-2 between April 2020 and November 30, 2021. Patients' data were extracted from LHS central data warehouse on December 30, 2021. For each COVID-19 episode, the date of the first positive PCR test was taken as the index date. Number of vaccine doses received were calculated at the index date. Diagnosis and laboratory data were queried as known 15 days before the index date. The following factors were included in the analysis: sex, age, the Body Mass Index (BMI) as a categorical variable (<18.5; 18.5-25; 25-30; 30-35;  $\geq$ 35), hemoglobin A1C range (<6.5; 6.5-8; 8-10;  $\geq$ 10), last glomerular filtration rate (GFR) as an estimate of kidney function as a categorical variable (categories:  $\geq$ 90; 60-89; 45-59; 30-44; <30). Presence of comorbidity conditions was assessed by presence of an active chronic diagnosis at this date. Chronic diagnoses, coded according to the International Classification of Diseases 9th revision (ICD-9), are regularly added, updated or ended, by the treating physician, at each encounter. The validity of chronic diagnoses in the registry has been previously examined and confirmed as high<sup>31-33</sup>.

To keep the models as simple as possible, we deliberately limited the models to the conditions that we identified as having the most significant effect on disease severity: hypertension, chronic obstructive pulmonary disease (COPD) and malignancy (solid or hematologic). Individuals who had a pregnancy diagnosis up to 210 days before the PCR test were excluded, as hospitalization would often pertain to pregnancy surveillance or delivery, and not reflect disease severity.

#### **Ethics statement**

The study protocol was approved by the statutory clinical research committee of Leumit Health Services and the Shamir Medical Center Institutional Review Board (129-2-LEU). Informed consent was waived because this is a large-scale retrospective study and all data were deidentified.

#### SARS-CoV-2 testing by real-time RT-PCR

Nasopharyngeal swabs were taken and examined for SARS-CoV-2 by real-time RT-PCR performed with internal positive and negative controls, according to World Health Organization guidelines, using TaqPath<sup>™</sup> COVID-19 Combo Kit (Thermo Fisher Scientific) and COBAS SARS-Cov-2 6800/8800 (Roche Diagnostics) assays.

#### Statistical analyses

Standard descriptive statistics were used to present the demographic characteristics of individuals included in the study cohort. Statistical analyses were done with R version 4.0.4 (R Foundation for Statistical Computing). Multivariable logistic regression models were fitted using the "glm" procedure, using age as a continuous variable, sex as a binary variable, number of vaccine doses, BMI category, hemoglobin A1C range, and GFR estimate<sup>34</sup> as categorical variables; and presence of hypertension, pulmonary disease or malignancy as binary variables. For categorical variables, missing values were treated as a separate "missing" category. This allowed to include in the analysis individuals with missing data, without making assumptions about the actual value of the variable. The receiver operating characteristic (ROC) curve was used to assess model performance<sup>35</sup>, using 10-fold cross-validation. A two-sided P<0.05 was considered statistically significant.

#### Results

#### Factors associated with hospitalization of SARS-CoV-2 positive individuals

101,034 COVID-19 episodes were included, based on a positive test for SARS-CoV-2 obtained between April 1, 2020 and November 30, 2021. 393 (0.4%) resulted in patient death during hospitalization or within 30 days of the disease, and 1,752 (1.7%) required patient hospitalization for COVID-19 that did not end in patient death.

**Table 1** shows the baseline characteristics of individuals included in the cohort, according to their outcomes. Generally, patients hospitalized and who died of the disease were older, had a greater proportion of males, had higher BMIs and hemoglobin A1C values, and were more likely to be affected with hypertension, pulmonary disease, malignancy, and impaired kidney function. Based on the features described above, we built multivariable logistic regression models to predict both the hospitalization and mortality outcomes. The odds ratios from multivariable regression models reflect the extent with which each risk factor affects the outcome, after adjustment for the others.

**Table 2** displays the model for hospitalization risk based on the comparison of 2,145 episodes that resulted either in hospitalization or death vs. 98,889 infections that did not necessitate hospitalization. For each variable, the regression coefficient, with the corresponding odds ratio and 95% confidence interval and p-values are displayed. The footnote explains how to calculate the outcome probability for any given patient data.

We emphasize a few key findings arising from the multivariable regression analysis. First, increased age is significantly associated with the risk of hospitalization: each year of age increases the odds for hospitalization by a multiplicative factor of 1.058, which means that compared to an individual aged twenty with similar other risk factors, a patient aged sixty is 10 times more likely to get hospitalized, and a patient aged eighty, 30 times more likely to get hospitalized. Female sex reduces odds for hospitalization by 34%. Obesity increases its risk in a gradual manner (OR=1.292 for BMI between 25 and 30, OR=1.611 for BMI between 30-35, and

OR=2.792 for BMI over 35, compared to the reference category of normal BMI, p<0.001 for all). Diabetes mellitus, as reflected by most recent hemoglobin A1C values is independently associated with increased risk in a gradual manner (OR=1.455 for A1C between 6.5 and 8%, OR=1.889 for A1C between 8 and 10%, and OR=3.017 for A1C above 10% compared to the reference category of A1C below 6.5%, p<0.001 for all). Impaired kidney function is also associated with increased risk in a gradual manner (OR=1.633 for GFR between 45 and 59, OR=2.291 for GFR between 30 and 44, and OR=3.876 for GFR below 30 compared to the reference category of GFR above 90, p<0.001 for all). Hospitalization risks significantly increase with hypertension (OR=1.269, 95% CI [1.130-1.426]), pulmonary disease (OR=1.338, 95% CI [1.140-1.569]) and cancer (OR=1.205, 95% CI [1.038-1.397]).

As expected, compared to unvaccinated patients, vaccination significantly decreases the hospitalization risk with (OR= 0.598, 95% CI [0.517-0.692] for two vaccine doses and OR=0.336, 95% CI [0.236-0.465] for three vaccine doses, p<0.001 for both categories), and even for the relatively small group of single vaccinated individuals, with OR=0.810, 95% CI [0.683-0.960] (P<0.0153).

The ROC curve shows the diagnostic ability of a classifier as its discrimination threshold is varied. We performed a 10-fold cross validation and calculated the ROC curve to estimate the performance of our model (**Figure 1**). The performance of the hospitalization risk model was remarkably accurate, with an area under the curve (AUC) of 0.889. The model was able to predict 50%, 80% and 90% of hospitalizations, with respective specificities of 95.3%, 82.0% and 69.0%.

#### Factors associated with mortality for SARS-CoV-2 positive individuals

**Table 3** displays the model for mortality risk. It is based on the comparison of 393 fatal cases of COVID-19 compared to 101,021 disease episodes that did not end in patient death. The smaller size of the outcome group limits the power of the model, nevertheless a few factors are associated with a large statistically significant effect: Advanced age is even more strikingly associated with increased mortality risk. Each year of age increases the odds for death by a factor of 1.103: compared to an individual aged twenty with similar other risk factors, a patient aged sixty is 51 times more likely to die of the disease, and a patient aged eighty is 363 times more likely to die. Female sex is also associated with reduced risk of death, reducing this risk by about a half.

Both extreme obesity and underweight increased the risk of death (OR=1.911 for BMI above 35, and OR=2.422 for BMI below 18.5, compared to normal BMI), while other BMI categories were not significantly associated with death. Impaired kidney function was also associated with augmented mortality risk in a gradual manner (OR=1.887 for GFR between 45 and 59, OR=2.701 for GFR between 30 and 44, and OR=5.894 for GFR below 30 compared to the reference category of GFR above 90, p<0.001 for all). Diabetes mellitus, as reflected by last hemoglobin A1C also increases mortality risk in a gradual manner, although more moderately than for hospitalization. The other comorbidities coefficients are overall similar to those for

hospitalization, although the smaller outcome group allowed to detect statistical significance only for hypertension and pulmonary disease. Vaccination with a booster dose significantly decreased the mortality risk by 78% (OR= 0.220, 95% CI [0.089-0.543], p=0.001).

We performed a 10-fold cross validation and plotted the ROC curve to estimate the performance of the mortality risk model (**Figure 2**). The model was very accurate, with an AUC of 0.967, and was able to predict 50%, 80% and 90% of death events, with respective specificities of 98.6%, 94.9% and 91.2%.

#### **Risk calculators**

**Tables 2 and 3** provide all the coefficients, as well as the formula that is used to calculate the absolute risk of a given individual, using the regression models described above. Basically, the coefficients are to be multiplied by the corresponding variables and summed to obtain the natural logarithm of the odds ratio. After exponentiation, the odds ratio can be converted to a probability by dividing it by its value plus one. This calculator is made available online and can be used to calculate hospitalization and mortality probabilities for any given individual.

#### Discussion

This study developed models that can estimate the risks of subsequent hospitalization and death for any individual newly infected with SARS-CoV-2, using health records from a large healthcare provider in Israel. It also provides further large-scale confirmation of recently published studies from other Israeli health care providers that showed that a third, booster vaccine provides a sharp and almost immediate increase in protection<sup>36,37</sup>. Considering that vaccination has also been shown to substantially decrease the risk for symptomatic infection, its overall cumulative effect on hospitalization and death are even much greater than the odds ratio reported here.

Our study capitalizes on the centrally managed, comprehensive electronic health records maintained in our health organization, that are continuously updated with hospitalization and death from COVID-19; the early adoption of a homogenous vaccination program in Israel, and of the booster dose; and the relatively large number of individuals that have been tested positive for COVID-19. We deliberately opted for model simplicity by limiting the number of input variables to recognized clinical factors associated with disease severity that are documented in most health organizations. We intentionally did not include country specific demographic variables, to generate a model that is generalizable to other populations. Even with these limited inputs, the resulting AUCs are highly accurate, achieving 0.889 for hospitalization and 0.967 for mortality. The better AUC performance of the model for mortality risk likely reflects that death is mostly determined by the patient health status, while the decision to hospitalize a patient is additionally impacted by availability of family or social support at home and the patient's own preferences, which are not accounted for by our model. Importantly, these mortality and hospitalization risk estimates can be given as soon as the disease is diagnosed, allowing to identify which patients are most at risk for a severe course, so that they could be given treatment

early in the infection. The models can also prioritize which populations to vaccinate, or urged to receive booster doses, to maximize lives saved and to reduce the load on hospitalization facilities. Several attempts have already been made to build predictive models for COVID-19 severity, notably <sup>4,16,28,38,39</sup>. Nevertheless, there is still an unmet need for simple models, which like CURB-65<sup>40</sup>, could allow instant triage of new patients, using few essential parameters, including vaccination status. This approach allowed us to produce models with remarkably high accuracy.

Interestingly and importantly, in contrast to what we and others found for the infection risk<sup>31</sup>, we did not observe that time elapsed since vaccination significantly increased hospitalization and mortality risks. For these outcomes, the protective effect of vaccination was largely determined by the cumulative number of vaccine doses received. This may indicate that the immune system response elicited by mRNA vaccine injection has a more lasting effect on hospitalization and mortality risk than on the risk of symptomatic infection following exposure to the virus.

Our study has several limitations. First, it is based on a population which was vaccinated almost exclusively with the Pfizer/Biotech BNT162b2 vaccine, and with the first two doses spaced by 21 days. It is uncertain how the estimated effect of vaccination under these conditions would apply to populations vaccinated using different vaccines or using a different vaccination schedule. Moreover, factors specific to our health organization may have affected the results, such as criteria for hospital admission, and treatment decisions that influence mortality. Evolving patient management policies could have a confounding effect on the number of vaccine doses at different times. Last, we have yet to assess the model ability to predict disease severity with new viral variants, such as the recently spreading Omicron. Additional studies in different populations would help to ascertain the validity of our models in different settings. To enable such validation studies, we provide the full model formulas and encourage their use.

In conclusion, the models described here, and available online as a calculator, allows to identify individuals most at risk for severe disease or death if infected, using very few essential parameters and vaccination status. This approach can guide public health decisions to optimally allocate vaccines and scarce medicines to maximize lives saved<sup>5</sup>.

#### Calculator address: <a href="https://covidest.web.app/">https://covidest.web.app/</a>

This research was supported in part by the Intramural Research Program, National Institutes of Health, National Cancer Institute, Center for Cancer Research. The content of this publication does not necessarily reflect the views or policies of the Department of Health and Human Services, nor does mention of trade names, commercial products, or organizations imply endorsement by the U.S. Government.

The authors had no conflict of interest to report

- Fan Y, Chan KH, Hung IFN. Safety and efficacy of COVID-19 vaccines: A systematic review and meta-analysis of different vaccines at phase 3. Vaccines [Internet] 2021;9(9):989. Available from: http://www.ncbi.nlm.nih.gov/pubmed/34579226
- Samaranayake LP, Seneviratne CJ, Fakhruddin KS. Coronavirus disease 2019 (COVID-19) vaccines: A concise review. Oral Dis [Internet] 2021; in press. Available from: http://www.ncbi.nlm.nih.gov/pubmed/33991381
- 3. Dyer O. Covid-19: FDA expert panel recommends authorising molnupiravir but also voices concerns. Bmj [Internet] 2021 [cited 2021 Dec 28];375:n2984. Available from: https://pubmed.ncbi.nlm.nih.gov/34857644/
- 4. Ioannou GN, Green P, Fan VS, et al. Development of COVIDVax Model to Estimate the Risk of SARS-CoV-2-Related Death among 7.6 Million US Veterans for Use in Vaccination Prioritization. JAMA Netw Open [Internet] 2021;4(4):e214347. Available from: http://www.ncbi.nlm.nih.gov/pubmed/33822066
- 5. Patel MK. Booster Doses and Prioritizing Lives Saved. N Engl J Med [Internet] 2021; 385(26):2476-7. Available from: http://www.ncbi.nlm.nih.gov/pubmed/34879192
- Persad G, Peek ME, Shah SK. Fair Allocation of Scarce Therapies for COVID-19. Clin Infect Dis [Internet] 2021; in press. Available from: http://www.ncbi.nlm.nih.gov/pubmed/34922352
- Rosen B, Waitzberg R, Israeli A. Israel's rapid rollout of vaccinations for COVID-19. Isr J Health Policy Res [Internet] 2021;10(1):6. Available from: http://www.ncbi.nlm.nih.gov/pubmed/33499905
- 8. Raz A, Keshet Y, Popper-Giveon A, Karkabi MS. One size does not fit all: Lessons from Israel's Covid-19 vaccination drive and hesitancy. Vaccine 2021;39(30):4027–8.
- 9. Dennis JM, Mateen BA, Sonabend R, et al. Type 2 diabetes and covid-19– related mortality in the critical care setting: A national cohort study in england, march–july 2020. Diabetes Care [Internet] 2021;44(1):50–7. Available from: http://www.ncbi.nlm.nih.gov/pubmed/33097559
- Drucker DJ. Diabetes, obesity, metabolism, and SARS-CoV-2 infection: the end of the beginning. Cell Metab [Internet] 2021;33(3):479–98. Available from: http://www.ncbi.nlm.nih.gov/pubmed/33529600
- 11. Gimeno-Miguel A, Bliek-Bueno K, Poblador-Plou B, et al. Chronic diseases associated with increased likelihood of hospitalization and mortality in 68,913 COVID-19 confirmed cases in Spain: A population-based cohort study. PLoS One [Internet] 2021;16(11 November):e0259822. Available from: http://www.ncbi.nlm.nih.gov/pubmed/34767594
- 12. Hamer M, Gale CR, Kivimäki M, Batty GD. Overweight, obesity, and risk of hospitalization for COVID-19: A community-based cohort study of adults in the United Kingdom. Proc Natl Acad Sci U S A [Internet] 2020;117(35):21011–3. Available from: http://www.ncbi.nlm.nih.gov/pubmed/32788355
- 13. Longmore DK, Miller JE, Bekkering S, et al. Diabetes and overweight/obesity are independent, nonadditive risk factors for in-hospital severity of covid-19: An

international, multicenter retrospective meta-analysis. Diabetes Care [Internet] 2021;44(6):1281–90. Available from: http://www.ncbi.nlm.nih.gov/pubmed/33858854

- 14. Zaki N, Alashwal H, Ibrahim S. Association of hypertension, diabetes, stroke, cancer, kidney disease, and high-cholesterol with COVID-19 disease severity and fatality: A systematic review. Diabetes Metab Syndr Clin Res Rev [Internet] 2020;14(5):1133–42. Available from: http://www.ncbi.nlm.nih.gov/pubmed/32663789
- Oetjens MT, Luo JZ, Chang A, et al. Electronic health record analysis identifies kidney disease as the leading risk factor for hospitalization in confirmed COVID-19 patients. PLoS One [Internet] 2020;15(11 November):e0242182. Available from: http://www.ncbi.nlm.nih.gov/pubmed/33180868
- Lian Z, Li Y, Wang W, et al. The Prediction Model of Risk Factors for COVID-19 Developing into Severe Illness Based on 1046 Patients with COVID-19. Emerg Med Int 2021;2021:7711056.
- Gülsen A, König IR, Jappe U, Drömann D. Effect of comorbid pulmonary disease on the severity of COVID-19: A systematic review and meta-analysis. Respirology [Internet] 2021;26(6):552–65. Available from: http://www.ncbi.nlm.nih.gov/pubmed/33955623
- 18. Hosseinzadeh R, Goharrizi MASB, Bahardoust M, et al. Should all patients with hypertension be worried about developing severe coronavirus disease 2019 (COVID-19)? Clin Hypertens [Internet] 2021;27(1):3. Available from: http://www.ncbi.nlm.nih.gov/pubmed/33451360
- Jung Y, Wee JH, Kim JH, Choi HG. The effects of previous asthma and copd on the susceptibility to and severity of covid-19: A nationwide cohort study in south korea. J Clin Med [Internet] 2021;10(20). Available from: http://www.ncbi.nlm.nih.gov/pubmed/34682749
- Song J, Zeng M, Wang H, et al. Distinct effects of asthma and COPD comorbidity on disease expression and outcome in patients with COVID-19. Allergy Eur J Allergy Clin Immunol [Internet] 2021;76(2):483–96. Available from: http://www.ncbi.nlm.nih.gov/pubmed/32716553
- Czernichow S, Beeker N, Rives-Lange C, et al. Obesity Doubles Mortality in Patients Hospitalized for Severe Acute Respiratory Syndrome Coronavirus 2 in Paris Hospitals, France: A Cohort Study on 5,795 Patients. Obesity (Silver Spring) [Internet] 2020;28(12):2282–9. Available from: http://www.ncbi.nlm.nih.gov/pubmed/32815621
- 22. Recalde M, Roel E, Pistillo A, et al. Characteristics and outcomes of 627 044 COVID-19 patients living with and without obesity in the United States, Spain, and the United Kingdom. Int J Obes [Internet] 2021;45(11):2347–57. Available from: http://www.ncbi.nlm.nih.gov/pubmed/34267326
- 23. Xu J, Yang J, Chen J, Luo Q, Zhang Q, Zhang H. Vitamin D alleviates lipopolysaccharide-induced acute lung injury via regulation of the renin-angiotensin system. Mol Med Rep 2017;16(5):7432–8.
- 24. Cook TM. The importance of hypertension as a risk factor for severe illness and mortality

in COVID-19. Anaesthesia [Internet] 2020;75(7):976–7. Available from: http://www.ncbi.nlm.nih.gov/pubmed/32339251

- 25. Du Y, Zhou N, Zha W, Lv Y. Hypertension is a clinically important risk factor for critical illness and mortality in COVID-19: A meta-analysis. Nutr Metab Cardiovasc Dis [Internet] 2021 [cited 2021 Dec 21];31(3):745–55. Available from: /pmc/articles/PMC7831720/
- 26. Liang X, Shi L, Wang Y, et al. The association of hypertension with the severity and mortality of COVID-19 patients: Evidence based on adjusted effect estimates. J Infect [Internet] 2020 [cited 2021 Dec 21];81(3):e44–7. Available from: /pmc/articles/PMC7315979/
- Meng Y, Meng Y, Lu W, et al. Cancer history is an independent risk factor for mortality in hospitalized COVID-19 patients: A propensity score-matched analysis. J Hematol Oncol [Internet] 2020;13(1):75. Available from: http://www.ncbi.nlm.nih.gov/pubmed/32522278
- Experton B, Tetteh HA, Lurie N, et al. A predictive model for severe covid-19 in the medicare population: A tool for prioritizing primary and booster covid-19 vaccination. Biology (Basel) [Internet] 2021;10(11):1185. Available from: http://www.ncbi.nlm.nih.gov/pubmed/34827181
- 29. Machado-Alba JE, Valladales-Restrepo LF, Machado-Duque ME, et al. Factors associated with admission to the intensive care unit and mortality in patients with COVID-19, Colombia. PLoS One [Internet] 2021;16(11 November):e0260169. Available from: http://www.ncbi.nlm.nih.gov/pubmed/34797857
- 30. Vahey GM, McDonald E, Marshall K, et al. Risk factors for hospitalization among persons with COVID-19-Colorado. PLoS One [Internet] 2021;16(9 September):e0256917. Available from: http://www.ncbi.nlm.nih.gov/pubmed/34473791
- Israel A, Merzon E, Schäffer AA, et al. Elapsed time since BNT162b2 vaccine and risk of SARS-CoV-2 infection: test negative design study. Bmj [Internet] 2021 [cited 2021 Nov 25];375:e067873. Available from: https://www.bmj.com/content/375/bmj-2021-067873
- Rennert G, Peterburg Y. Prevalence of selected chronic diseases in Israel. Isr Med Assoc J [Internet] 2001;3(6):404–8. Available from: http://www.ncbi.nlm.nih.gov/pubmed/11433630
- 33. Hamood R, Hamood H, Merhasin I, Keinan-Boker L. A feasibility study to assess the validity of administrative data sources and self-reported information of breast cancer survivors. Isr J Health Policy Res 2016;5(1):50.
- 34. Levey AS, Coresh J, Greene T, et al. Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann Intern Med 2006;145(4):247–54.
- Lasko TA, Bhagwat JG, Zou KH, Ohno-Machado L. The use of receiver operating characteristic curves in biomedical informatics. J Biomed Inform [Internet] 2005;38(5):404–15. Available from: http://www.ncbi.nlm.nih.gov/pubmed/16198999

- 36. Arbel R, Hammerman A, Sergienko R, et al. BNT162b2 Vaccine Booster and Mortality Due to Covid-19. N Engl J Med [Internet] 2021; 385(26):2413-20 Available from: http://www.ncbi.nlm.nih.gov/pubmed/34879190
- 37. Bar-On YM, Goldberg Y, Mandel M, et al. Protection of BNT162b2 Vaccine Booster against Covid-19 in Israel. N Engl J Med [Internet] 2021;385(15):1393–400. Available from: http://www.ncbi.nlm.nih.gov/pubmed/34525275
- 38. Mamidi TKK, Tran-Nguyen TK, Melvin RL, Worthey EA. Development of An Individualized Risk Prediction Model for COVID-19 Using Electronic Health Record Data. Front Big Data [Internet] 2021;4:675882. Available from: http://www.ncbi.nlm.nih.gov/pubmed/34151259
- Hippisley-Cox J, Coupland CA, Mehta N, et al. Risk prediction of covid-19 related death and hospital admission in adults after covid-19 vaccination: national prospective cohort study. BMJ [Internet] 2021;374:n2244. Available from: http://www.ncbi.nlm.nih.gov/pubmed/34535466
- 40. Lim WS, Van Der Eerden MM, Laing R, et al. Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study. Thorax [Internet] 2003 [cited 2021 Dec 31];58(5):377. Available from: /pmc/articles/PMC1746657/?report=abstract

		Not hospitalized	Hospitalized (not deceased)	Deceased
N (%)		98,889 (97.9%)	1,752 (1.7%)	393 (0.4%)
0		82,265 (83.2 %)	1,407 (80.3 %)	295 (75.1 %)
Vaccines doses	1	4,728 (4.8 %)	137 (7.8 %)	32 (8.1 %)
	2	10,430 (10.5 %)	175 (10.0 %)	61 (15.5 %)
	3	1,466 (1.5 %)	33 (1.9 %)	5 (1.3 %)
Sex	Female	48,563 (49.1 %)	798 (45.5 %)	169 (43.0 %)
Age	mean (SD)	29.44 (19.17)	58.44 (19.03)	75.27 (13.06)
Age category	5-11	19,602 (19.8 %)	19 (1.1 %)	0 (0.0 %)
	12-17	15,998 (16.2 %)	30 (1.7 %)	0 (0.0 %)
	18-39	34,371 (34.8 %)	245 (14.0 %)	6 (1.5 %)
	40-59	20,361 (20.6 %)	561 (32.0 %)	44 (11.2 %)
	≥60	8,557 (8.7 %)	897 (51.2 %)	343 (87 3 %)
	Underweight < 18.5	22,506 (22.8 %)	44 (2.5 %)	10 (2.5 %)
BMI category	Normal 18.5 - 25	32,371 (32.7 %)	283 (16.2 %)	83 (21.1 %)
	Overweight 25 - 30	21,395 (21.6 %)	566 (32.3 %)	126 (32.1 %)
	Obese l 30 - 35	10,763 (10.9 %)	444 (25.3 %)	85 (21.6 %)
	Obese II+ ≥ 35	5,480 (5.5 %)	371 (21.2 %)	70 (17.8 %)
	*missing*	6,374 (6.4 %)	44 (2.5 %)	19 (4.8 %)
	G1 (Normal) ≥90	62,744 (63.4 %)	846 (48.3 %)	95 (24.2 %)
	G2 60-89	12,622 (12.8 %)	596 (34.0 %)	142 (36.1 %)
<b>Kidney function</b>	G3a 45-59	840 (0.8 %)	140 (8.0 %)	68 (17.3 %)
eGFR category	G3b 30-44	263 (0.3 %)	74 (4.2 %)	46 (11.7 %)
	G4/G5 <30	151 (0.2 %)	45 (2.6 %)	37 (9.4 %)
	*missing*	22,269 (22.5 %)	51 (2.9 %)	5 (1.3 %)
Hemoglobin A1C range	< 6.5	38,742 (92.2 %)	1,106 (72.2 %)	268 (70.7 %)
	[6.5, 8.0)	2,129 (5.1 %)	253 (16.5 %)	70 (18.5 %)
	[8.0, 10.0)	815 (1.9 %)	115 (7.5 %)	31 (8.2 %)
	≥ 10.0	328 (0.8 %)	58 (3.8 %)	10 (2.6 %)
	*missing*	56,875 (57.5 %)	220 (12.6 %)	14 (3.6 %)
Comorbidities	Hypertension	9,321 (9.4 %)	880 (50.2 %)	301 (76.6 %)
	Pulmonary Disease	1,592 (1.6 %)	167 (9.5 %)	74 (18.8 %)
	Malignancy	2,258 (2.3 %)	202 (11.5 %)	83 (21.1 %)

#### Table 1: Demographic and clinical characteristics of the study population

			Odds	95% Confidence	_	β
			Ratio	interval	Р	(coefficient)
βo	(Interce	ept)	0.001		0.0000	-6.534695
Age	continuous		1.058	[1.054-1.062]	0.0000	0.056413
Sex	Male	e	1.000	reference	2	0
	Female		0.654	[0.595-0.718]	0.0000	-0.425377
	0		1.000	reference		0
Vaccine doses	1		0.810	[0.683-0.960]	0.0153	-0.211030
	2		0.598	[0.517-0.692]	0.0000	-0.513469
	3		0.336	[0.239-0.472]	0.0000	-1.091126
	Underweight	< 18.5	1.107	[0.813-1.508]	0.5196	0.101560
	Normal	18.5 - 25	1.000	reference	9	0
BMI category	Overweight	25 - 30	1.292	[1.127-1.481]	0.0002	0.256289
Bivil category	Obese l	30 - 35	1.611	[1.392-1.864]	0.0000	0.476824
	Obese II+	≥ 35	2.792	[2.388-3.265]	0.0000	1.026788
	*missing*		1.542	[1.143-2.079]	0.0046	0.432789
	G1 (Normal)	≥ 90	1.000	reference	2	0
	G2	60-89	1.071	[0.959-1.196]	0.2238	0.068555
<b>Kidney</b> function	G3a	45-59	1.633	[1.351-1.975]	0.0000	0.490519
GFR category	G3b	30-44	2.291	[1.777-2.952]	0.0000	0.828816
	G4/G5	<30	3.876	[2.848-5.276]	0.0000	1.354833
	*missiı	ng*	0.761	[0.556-1.040]	0.0867	-0.273687
	< 6.5	5	1.000	reference		0
Homoglahin	[6.5, 8	.0)	1.455	[1.264-1.676]	0.0000	0.375189
Hemoglobin A1C range	[8.0, 10	D.O)	1.889	[1.546-2.309]	0.0000	0.636220
	≥ 10.	0	3.017	[2.265-4.018]	0.0000	1.104235
	*missiı	ng*	0.732	[0.614-0.873]	0.0005	-0.311599
Comorbidities	Hypertei	nsion	1.269	[1.130-1.426]	0.0001	0.238422
	Pulmonary	Disease	1.338	[1.140-1.569]	0.0004	0.291024
	Maligna	ancy	1.205	[1.038-1.397]	0.0141	0.186095

\* Odds ratio is defined as Exp(coefficient).

Coefficients in the last column are the  $\beta_i$  to be used to calculate the odds ratio, using the following formula: Odds Ratio = Exp ( $\beta_0 + x_1 \beta_1 + x_2 \beta_2 + x_3 \beta_3 + x_4 \beta_3 + ...$ )


Probability of event can be obtained from the odds ratio, using the formula: p = (Odds Ratio) / (1 + Odds Ratio)

			Odds Ratio	95% Confidence interval	Р	β <sub>i</sub> (coefficient)
βo	(Intercept)		0.000		0.0000	-11.048886
Age	continuous in years		1.103	[1.093-1.114]	0.0000	0.09825
<b>C</b>	Male		1.000	reference		0
Sex	Female		0.497	[0.399-0.621]	0.0000	-0.698512
	0		1.000	reference		0
Vaccine doses	1		0.922	[0.627-1.356]	0.6790	-0.081442
	2		0.949	[0.708-1.273]	0.7282	-0.051963
	3		0.220	[0.089-0.543]	0.0010	-1.515007
	Underweight	< 18.5	2.422	[1.171-5.009]	0.0171	0.88445
BMI category	Normal	18.5 - 25	1.000	reference		0
	Overweight	25 - 30	0.958	[0.712-1.288]	0.7749	-0.043287
	Obese l	30 - 35	1.065	[0.767-1.477]	0.7081	0.062557
	Obese ll+	≥ 35	1.911	[1.341-2.723]	0.0003	0.647439
	*missing*		2.035	[1.151-3.599]	0.0146	0.71046
	G1 (Normal)	≥ 90	1.000	reference	1	0
	G2	60-89	1.176	[0.890-1.555]	0.2533	0.162541
Kidney function GFR category	G3a	45-59	1.887	[1.319-2.701]	0.0005	0.635119
	G3b	30-44	2.701	[1.779-4.101]	0.0000	0.993582
	G4/G5	<30	5.894	[3.731-9.310]	0.0000	1.773895
	*missi	*missing*		[0.670-5.781]	0.2184	0.676774
	< 6.5	5	1.000	reference		0
Hemoglobin	[6.5, 8	.0)	1.167	[0.875-1.558]	0.2936	0.154653
A1C	[8.0, 10	0.0)	1.464	[0.974-2.199]	0.0664	0.381174
range	≥ 10.	0	1.841	[0.936-3.620]	0.0771	0.610139
	*missi	ng*	0.451	[0.232-0.878]	0.0191	-0.795335
Comorbidities	Hyperte	nsion	1.366	[1.024-1.821]	0.0338	0.311723
	Pulmonary	Disease	1.471	[1.109-1.951]	0.0073	0.386085
	Maligna	ancy	1.164	[0.889-1.523]	0.2687	0.151799

\* Odds ratio is defined as Exp(coefficient).


Coefficients in the last column are the  $\beta_i$  to be used to calculate the odds ratio, using the following formula: Odds Ratio = Exp ( $\beta_0 + x_1 \beta_1 + x_2 \beta_2 + x_3 \beta_3 + x_4 \beta_3 + ...$ )

Probability of event can be obtained from the odds ratio, using the formula: p = ( Odds Ratio ) / (1 +Odds Ratio)





The ROC curve shows the sensitivity and the specificity of the hospitalization model as its discrimination threshold is varied. With a threshold of 8.93% for risk, 50% of the COVID-19 episodes necessitating hospitalization can be identified (sensitivity=50%), and specificity is 95.3% (false positive rate=4.7%); with a risk threshold of 2.39%, sensitivity is 80% and specificity is 82.0% (false positive rate=8.0%); with a risk threshold of 1.06%, sensitivity is 90% and specificity is 69.0% (false positive rate=31.0%).





The ROC curve shows the sensitivity and the specificity of the mortality model as its discrimination threshold is varied. With a threshold of 5.52% for risk, 50% of the COVID-19 episodes ending in patient death can be identified (sensitivity=50%), and specificity is 98.6% (false positive rate=1.4%); with a risk threshold of 1.25%, sensitivity is 80% and specificity is 94.9% (false positive rate =5.1%); with a risk threshold of 0.59%, sensitivity is 90% and specificity is 91.2% (false positive rate=8.8%).

